Sign In
Buy BYSI
$1.15
+0.0200 (+1.77%)
At Close: Jul 31, 2026
JPMorgan Chase & Co. Has $200,000 Position in BeyondSpring Inc. (NASDAQ:BYSI)
09:10am, Monday, 15'th Nov 2021 Transcript Daily
JPMorgan Chase & Co. lowered its holdings in BeyondSpring Inc. (NASDAQ:BYSI) by 65.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 19,141 shares of the company’s stock after selling 36,513 shares during the quarter. JPMorgan Chase & Co.’s holdings in BeyondSpring […]
3 Biotech Stocks With Huge Catalysts Incoming
06:13am, Friday, 22'nd Oct 2021
These drugmakers have big events that should occur before the end of 2021.
Why Are BeyondSpring's Shares Plunging Today?
02:22pm, Monday, 20'th Sep 2021
BeyondSpring Pharmaceuticals Inc (NASDAQ: BYSI) shared the final intention-to-treat (ITT) dataset from its DUBLIN-3 Phase 3 trial of plinabulin. The trial evaluated plinabulin combined with docetax
Here's why BeyondSpring shares are up more than 25% on Monday
01:14pm, Monday, 20'th Sep 2021
Shares of BeyondSpring Inc (NASDAQ: BYSI) gained more than 200% in August as the pharmaceutical company said its candidate drug (Plinabulin) improved life expectancy for patients with advanced lung ca
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology (ESMO) 2021 Congress
07:30am, Monday, 20'th Sep 2021
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer
Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns
08:27pm, Friday, 17'th Sep 2021
BeyondSpring Pharmaceuticals has the potential to address the billion-dollar anti-cancer markets on top of a large unmet medical need to reduce chemo-induced neutropenia (CIN) with revenues beginning
BeyondSpring Presents New Plinabulin Data At ESMO Congress
11:50am, Thursday, 16'th Sep 2021
BeyondSpring Pharmaceuticals (NASDAQ: BYSI) announced new plinabulin data from its chemotherapy-induced neutropenia (CIN) prevention program at the European Society for Medical Oncology (ESMO21) 20
Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021. Plinabulin in
BeyondSpring: Q2 Earnings Insights
07:22am, Tuesday, 14'th Sep 2021
BeyondSpring(NASDAQ:BYSI) stock fell by 4.13% on Monday after the company reported their Q2 earnings results on Friday, September 10, 2021 at 07:00 AM. Here's what investors need to know about the ann
BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2021 Results - Earnings Call Transcript
02:20pm, Friday, 10'th Sep 2021
BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2021 Results - Earnings Call Transcript
BeyondSpring Inc. (BYSI) Reports Q2 Loss, Misses Revenue Estimates
10:51am, Friday, 10'th Sep 2021
BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 0.00% and -97.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
07:00am, Friday, 10'th Sep 2021
- Management to host a call today at 8:00 am ET - Management to host a call today at 8:00 am ET
Baird Initiates BeyondSpring With Outperform On Plinabulin Potential
06:08pm, Thursday, 09'th Sep 2021
BeyondSpring Inc's (NASDAQ:BYSI) lead candidate plinabulin is likely to receive approval around the Nov. 30 PDUFA date for chemotherapy-induced neutropenia (CIN), according to Baird. The BeyondSpring
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, t
BeyondSpring to Participate in the Upcoming September Conferences
05:54pm, Wednesday, 08'th Sep 2021
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today
